Table 2.

Ongoing clinical trials for BAFF and/or APRIL targeted therapies in human autoimmune and cancer diseases (http://www.clinicaltrials.gov, March 2013).

Disease	Drug	Mechanism of action	Trial	Status	Phase
SLE	Blisibimod	Anti-BAFF	NCT01305746	Active	II
			NCT01395745	Not yet recruiting	III
	Belimumab	Anti-BAFF	NCT01597622	Recruiting	III
			NCT01484496	Recruiting	III
			NCT01597492	Recruiting	IV
			NCT01705977	Not yet recruiting	IV
			NCT01632241	Not yet recruiting	IV
			NCT00724867	Active	III
			NCT01345253	Recruiting	III
			NCT00712933	Active	III
			NCT00583362	Active	II
			NCT01639339	Recruiting	III
	Tabalumab	Anti-BAFF	NCT01205438	Recruiting	III
			NCT01196091	Recruiting	III
			NCT01488708	Recruiting	III
Pediatric SLE	Belimumab	Anti-BAFF	NCT01649765	Recruiting	II
RA	Tabalumab	Anti-BAFF	NCT01676701	Active	III
			NCT01253291	Active	I
			NCT01215942	Active	III
			NCT01202773	Active	III
			NCT01202760	Active	III
			NCT01198002	Active	III
			NCT01576549	Active	II
MG	Belimumab	Anti-BAFF	NCT01480596	Not yet recruiting	II
Diffuse cutaneous systemic sclerosis	Belimumab	Anti-BAFF	NCT01670565	Recruiting	II
Wegener's granulomatosis or microscopic polyangiitis	Belimumab	Anti-BAFF	NCT01663623	Not yet recruiting	III
Granulomatosis with polyangiitis microscopic polyangiitis	Blisibimod	Anti-BAFF	NCT01598857	Not yet recruiting	II
End-stage renal disease	Tabalumab	Anti-BAFF	NCT01200290	Active	II
Idiopathic membranous glomerulonephropathy	Belimumab	Anti-BAFF	NCT01762852	Not yet recruiting	II
			NCT01610492	Recruiting	II
Immune thrombocytopenic purpura	Blisibimod	Anti-BAFF	NCT01609452	Not yet recruiting	II/III
Chronic ITP	Belimumab	Anti-BAFF	NCT01440361	Not yet recruiting	II
Symptomatic WM	Belimumab	Anti-BAFF	NCT01142011	Recruiting	II
Relapsed or refractory MM	Tabalumab	Anti-BAFF	NCT00689507	Active	I
			NCT01556438	Recruiting	I
Previously treated MM	Tabalumab	Anti-BAFF	NCT01602224	Recruiting	II/III
Prevention of kidney transplant rejection	Belimumab	Anti-BAFF	NCT01536379	Not yet recruiting	II

APRIL, a proliferation inducing ligand; BAFF, B cell activating factor of the tumor necrosis factor (TNF) family; ITP, immune thrombocytopenia; MG, myasthenia gravis; MM, multiple myeloma; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WM, Waldenström macroglobulinemia.